FLUZONE QUADRIVALENT National Drug Code Directory

Similar documents
FLUZONE INTRADERMAL QUADRIVALENT National Drug Code Directory

HAVRIX National Drug Code Directory

FLUCELVAX QUADRIVALENT (PREFILLED SYRINGE) National Drug Code Directory

National Drug Code Directory

PHENYTOIN SODIUM National Drug Code Directory

SODIUM BICARBONATE National Drug Code Directory

DEXAMETHASONE SODIUM PHOSPHATE National Drug Code Directory

MYCAMINE National Drug Code Directory

DIVALPROEX SODIUM National Drug Code Directory

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 20/5/12.5 MG National Drug Code Directory

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE National Drug Code Directory

DAPTACEL National Drug Code Directory

SHEER COVER MINERAL FOUNDATION National Drug Code Directory

POTASSIUM CITRATE CITRIC ACID CRYSTALS National Drug Code Directory

ANTICOAGULANT CITRATE DEXTROSE A ACD-A National Drug Code Directory

SUBSYS National Drug Code Directory

National Drug Code Directory

PRIMAXIN National Drug Code Directory

KETAMINE HYDROCHLORIDE National Drug Code Directory

DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE National Drug Code Directory

MORPHINE SULFATE National Drug Code Directory

National Drug Code Directory

DIANEAL LOW CALCIUM WITH DEXTROSE National Drug Code Directory

National Drug Code Directory

CITRANATAL DHA National Drug Code Directory

PEDIATRIC INFUVITE MULTIPLE VITAMINS FOR INFUSION National Drug Code Directory

O-CAL FA MULTIVITAMIN National Drug Code Directory

THYRO T3 RESCUE National Drug Code Directory

FOLET DHA National Drug Code Directory

ADRENAL SUPPORT National Drug Code Directory

HERPES SIMPLEX PLUS National Drug Code Directory

LYMPH/SPLEEN COMBO National Drug Code Directory

CLEANSE REMEDY WATER National Drug Code Directory

TRANQUIL REMEDY NO. 11 National Drug Code Directory

CALM REMEDY WATER National Drug Code Directory

BUG BITES - ITCH STOPPER National Drug Code Directory

WEBINAR 1 CODING FOR FLUZONE VACCINATION CODING AND BILLING FOR VACCINATION WITH FLUZONE, INFLUENZA VACCINES CRACKING THE CODES: UPDATED for

SANOFI PASTEUR INFLUENZA VACCINE PRESENTATIONS CODING AND BILLING CHECKLIST

Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

Over-the-Counter Pediatric Liquid Drug Products Containing Acetaminophen

Guidance for Industry

Q&A: Publicly Funded Seasonal Inactivated Influenza Vaccine Information for

Physician Injectable Drug List (PIDL) Department for Medicaid Services, HP, and Magellan Rx Management June 1, 2010

ANDA Labeling Question Based Review September 11, 2013 GPhA/FDA ANDA Labeling Workshop/USP User Forum

Naloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program

Influenza Immunization Drug Cards. New Brunswick (2017/18)

NDA NDA APPROVAL

New York State Department of Health. Notice of Voluntary Recall of Influenza A (H1N1) 2009 Monovalent Vaccine

Calcium Folinate Solution for Injection

Influenza Immunization Drug Cards. Nova Scotia (2017/18)

Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044

PACKAGE LEAFLET: INFORMATION FOR THE USER

Influenza Immunization Drug Cards. Ontario 2018/19

ORANGE BOOK ORANGE BOOK

ANDA Arthur P. Bedrosian, President Armenpharm, Ltd. 49 South Ridge Road P.O. Box D1400 Pomona, NY December 3, 2015

PACKAGE LEAFLET: INFORMATION FOR THE USER

CENTER FOR DRUG EVALUATION AND RESEARCH. APPLICATION NUMBER: Orig1s000 APPROVAL LETTER

2. WHAT YOU NEED TO KNOW BEFORE YOU OR YOUR CHILD USE INFLUENZA VACCINE

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Influenza Immunization Drug Cards. Ontario (2017/18)

Inspections, Compliance, Enforcement, and Criminal Investigations

Patient Information Leaflet: Information for the user

Influenza Immunization Drug Cards. Saskatchewan 2018/19

For the 2017/2018 Influenza Immunization Season. Patient Eligibility. Description. Ontario Public Drug Programs, Ministry of Health and Long-Term Care

Talkin Flu Mid-America Immunization Coalition August 18, William Atkinson, MD, MPH Immunization Action Coalition

Ontario Public Drug Programs, Ministry of Health and Long-Term Care. For the Influenza Immunization Season

Low Influenza Activity

Three-Month Extension of Certain Tobacco Product Compliance Deadlines Related to the

FluQuadri ; FluQuadri Junior Inactivated Quadrivalent Influenza Vaccine (Split Virion)

Summary: Sustained Influenza B Activity

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Decreasing Activity. Since Sept. 1, 2018: Hospitalizations: 93 ICU* admissions: 16 Deaths: 5. Syndromic in Community Syndromic in Care Syndromic in ED

Harmonization effort for OTC monograph in Taiwan. Ms. Hsueh-Yung (Mary) Tai Deputy Director, Division of Medical Product, Taiwan FDA

Low Influenza Activity

Summary: Low and Decreasing Activity

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

No Laboratory-confirmed Influenza Activity

FEB 28 A 9 :09

CONTAGIOUS COMMENTS Department of Epidemiology

Influenza Immunization Drug Cards. Alberta 2018/19

Influenza Immunization Drug Cards

4/26/2013. Libia Lugo Drug Specialist San Juan District Office Investigations Branch

Summary: Decreasing. Since Sept. 1, 2017: Hospitalizations: 363 ICU* admissions: 26 Deaths: 32

Summary: Increasing Activity

Summary: High Activity

Withdrawal of Proposed Rule on Supplemental Applications Proposing Labeling Changes for

Low Influenza Activity

Summary: High Activity

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

High Activity. Since Sept. 1, 2018: Hospitalizations: 62 ICU* admissions: 8 Deaths: <5. Syndromic in Community Syndromic in Care Syndromic in ED

Summary: Increasing Activity

Brand and Generic Drugs. Educational Objectives. Absorption

FLUZONE Quadrivalent

Mark M. Yacura. Partner

Transcription:

49281-418-50 FLUZONE QUADRIVALENT The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or processed by it for commercial distribution. (See Section 510 of the Federal Food, Drug, and Cosmetic Act (Act) (21 U.S.C. 360)). Drug products are identified and reported using a unique, three-segment number, called the National Drug Code (NDC), which serves as a universal product identifier for drugs. FDA publishes the listed NDC numbers and the information submitted as part of the listing information in the NDC Directory which is updated daily. 2019

49281-418-50 Fluzone Quadrivalent Labeler Sanofi Pasteur Inc. of Company corresponding to the labeler code segment of the ProductNDC. NDC Package Code 49281-418-50 The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC. Proprietary Fluzone Quadrivalent Also known as the trade name. It is the name of the product chosen by the labeler. 11 Digit NDC Code 49281-0418-50 It should be noted that many NDCs are displayed on drug packaging in a 10-digit format. Proper billing of an NDC requires an 11-digit number in a 5-4-2 format. Converting NDCs from a 10-digit to 11-digit format requires a strategically placed zero, dependent upon the 10-digit format. Product NDC 49281-418 The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. Product Type Non Proprietary Package Description VACCINE Influenza A Virus A/michigan/45/2015 X-275 (h1n1) Antigen (formaldehyde Inactivated), Influenza A Virus A/singapore/infimh- 16-0019/2016 Ivr-186 (h3n2) Antigen (formaldehyde Inactivated), Influenza B Virus B/phuket/3073/2013 Antigen (formaldehyde Inactivated), And Influenza B Virus B/maryland/15/2016 Bx- 69a Antigen (formaldehyde Inactivated) 10 SYRINGE, GLASS in 1 PACKAGE (49281-418-50) >.5 ml in 1 SYRINGE, GLASS (49281-418-88) Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the Document Type of the SPL submission for the listing. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. Sometimes called the generic name, this is usually the active ingredient(s) of the product. A description of the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. For example: 4 BOTTLES in 1 CARTON/100 TABLETS in 1 BOTTLE. - 2 -

Marketing Category BLA Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. Application Number BLA103914 This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. part 341 ). For unapproved drugs, this field will be null. Product Marketing Start Date 20180629 This is the date that the labeler indicates was the start of its marketing of the drug product. Dosage Form INJECTION, SUSPENSION The translation of the DosageForm Code submitted by the firm. The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. Route INTRAMUSCULAR The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. Substance INFLUENZA A VIRUS A/MICHIGAN/45/2015 X- 275 (H1N1) ANTIGEN INACTIVATED); INFLUENZA A VIRUS A/SINGAPORE/INFIMH- 16-0019/2016 IVR-186 (H3N2) ANTIGEN INACTIVATED); INFLUENZA B VIRUS B/PHUKET/3073/2013 ANTIGEN INACTIVATED); INFLUENZA B VIRUS B/MARYLAND/15/2016 BX-69A ANTIGEN INACTIVATED) This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. Strength Number 15; 15; 15; 15 These are the strength values (to be used with units below) of each active ingredient, listed in the same order as the Substance field above. Strength Unit ug/.5ml; ug/.5ml; ug/.5ml; ug/.5ml These are the units to be used with the strength values above, listed in the same order as the Substance and SubstanceNumber. - 3 -

Status Active NDC Code Status: <ul> <li><strong>active</strong> <br/>active NDC Code</li> <li><strong>deprecated</strong> <br/>deprecated NDC Code</li> <li> <strong>unfinished</strong> (Unapproved) <br/>the following status describes submitted unfinished drugs, including the marketing categories of Active Pharmaceutical Ingredient (API), Drug for Further Processing, Bulk for Human Drug Compounding, and Bulk for Animal Drug Compounding. <br/> <strong> FDA does not review and approve unfinished products. Therefore, all products having "unfinished" status are considered unapproved. </strong> </li> </ul> Last Update Date 2018-08-06 The date that a record was last updated or changed. - 4 -

Food and Drug Administration Center for Drug Evaluation and Research Office of Compliance, Immediate Office Drug Registration and Listing Team 10903 New Hampshire Ave Silver Spring, MD 20993-0002 Email: edrls@fda.hhs.gov - 5 -

For all questions regarding this bundle please contact Support@HIPAASpace.com. Also feel free to let us know about any suggestions or concerns. All additional information as well as customer support is available at http://. - 6 -